Exelixis to speed up cancer compound review on Glaxo's request

Aug 23 (Reuters) - Exelixis Inc (EXEL.O) said it agreed to speed up a review of a cancer compound, XL880, after GlaxoSmithKline Plc (GSK.L) asked for a review of the compound before it reaches proof-of-concept.

The biotechnology company said in a statement it expects to deliver the information to Glaxo in mid-September, at which point Glaxo will begin its review to determine whether or not to select XL880 for further development and commercialization. (Reporting by Neha Pathania in Bangalore)